| Product Name | CTGF ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Connective Tissue Growth Factor (CTGF). No significant cross-reactivity or interference between Connective Tissue Growth Factor (CTGF) and analogues was observed. |
| Synonyms | CCN2; HCS24; IGFBP8; NOV2; Insulin-Like Growth Factor-Binding Protein 8; Hypertrophic Chondrocyte-Specific Protein 24; CCN Family Member 2 |
| Method | Sandwich |
| Detection Range | 7.8-500pg/mL |
| Sensitivity | 3.5pg/mL |
| Target | CTGF |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Connective Tissue Growth Factor (CTGF). No significant cross-reactivity or interference between Connective Tissue Growth Factor (CTGF) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P29279 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model;Connective tissue growth factor hammerhead ribozyme attenuates human hepatic stellate cell function;Activation of JNK Signaling Mediates Connective Tissue Growth Factor Expression and Scar Formation in Corneal Wound Healing;Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy;Connective tissue growth factor (CTGF/CCN2): A protagonist in cardiac allograft vasculopathy development?;Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis;Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis;Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy;Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models;Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis;Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy;Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR;The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence;Molecular mechanisms underlying fibrosis and elastin destruction in childhood interstitial lung diseases;Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR;12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.;Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.;TGFβ mediates collagen production in human CRSsNP nasal mucosa‐derived fibroblasts through Smad2/3‐dependent pathway and CTGF induction and secretion;Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with …;Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure;MicroRNAs and ventricular remodeling in aortic stenosis;Manuscript title Microparticles Containing MiR-625-5p In Coronary Artery Reduce Myocardial Fibrosis After Myocardial Infarction; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA010Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
